Search
glucose, insulin, K+ (GIK)
Contraindications:
Does NOT improve outcomes after acute myocardial infarction.
Patients without heart failure may benefit. [1]
Patients with heart failure may be harmed.
No benefit after thrombolysis in patient with STEMI [2]
- no benefit in subgroups (diabetes, heart failure) [2]
Dosage:
- 8-12 hour IV infusion
General
pharmacologic combination
References
- Journal Watch 23(24):191, 2003
van der Horst ICC et al
Glucose-insulin-potassium infusion inpatients treated with
primary angioplasty for acute myocardial infarction: the
glucose-insulin-potassium study: a randomized trial.
J Am Coll Cardiol 42:784, 2003
PMID: 12957421
Apstein CS
The benefits of glucose-insulin-potassium for acute myocardial
infarction (and some concerns).
J Am Coll Cardiol 42:792, 2003
PMID: 12957422
- Journal Watch 25(5):38, 2005
Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E,
Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L;
CREATE-ECLA Trial Group Investigators.
Effect of glucose-insulin-potassium infusion on mortality in
patients with acute ST-segment elevation myocardial infarction:
the CREATE-ECLA randomized controlled trial.
JAMA. 2005 Jan 26;293(4):437-46.
PMID: 15671428
Components
glucose (dextrose, D-glucose)
insulin
K+